PMCA generated prions from the olfactory mucosa of patients with Fatal Familial Insomnia cause prion disease in mice

  1. Edoardo Bistaffa
  2. Alba Marín Moreno
  3. Juan Carlos Espinosa
  4. Chiara Maria Giulia De Luca
  5. Federico Angelo Cazzaniga
  6. Sara Maria Portaleone
  7. Luigi Celauro
  8. Giuseppe Legname
  9. Giorgio Giaccone
  10. Juan Maria Torres
  11. Fabio Moda  Is a corresponding author
  1. Fondazione IRCCS Istituto Neurologico Carlo Besta, Italy
  2. Centro de Investigación en Sanidad Animal (CISA-INIA), Spain
  3. ASST Santi Paolo e Carlo Università Degli Studi di Milano, Italy
  4. Scuola Internazionale Superiore Di Studi Avanzati (SISSA), Italy

Abstract

Background: Fatal Familial Insomnia (FFI) is a genetic prion disease caused by the D178N mutation in the prion protein gene (PRNP) in coupling phase with methionine at PRNP 129. In 2017, we have shown that the olfactory mucosa (OM) collected from FFI patients contained traces of PrPSc detectable by Protein Misfolding Cyclic Amplification (PMCA).

Methods In this work, we have challenged PMCA generated products obtained from OM and brain homogenate of FFI patients in BvPrP-Tg407 transgenic mice expressing the bank vole prion protein to test their ability to induce prion pathology.

Results: All inoculated mice developed mild spongiform changes, astroglial activation and PrPSc deposition mainly affecting the thalamus. However, their neuropathological alterations were different from those found in the brain of BvPrP-Tg407 mice injected with raw FFI brain homogenate.

Conclusions: Although with some experimental constraints, we show that PrPSc present in OM of FFI patients is potentially infectious.

Funding: This work was supported in part by the Italian Ministry of Health (GR-2013-02355724 and Ricerca Corrente), MJFF, ALZ, Alzheimer's Research UK and the Weston Brain Institute (BAND2015), and Euronanomed III (Speedy) to FM; by the Spanish Ministerio de Economía y Competitividad [grant AGL2016-78054-R (AEI/FEDER, UE)] to J.M.T. and J.C.E.; A.M.-M. was supported by a fellowship from the INIA (FPI-SGIT-2015-02).

Data availability

All data generated or analyzed during this study are included in the manuscript.

Article and author information

Author details

  1. Edoardo Bistaffa

    Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
    Competing interests
    The authors declare that no competing interests exist.
  2. Alba Marín Moreno

    Centro de Investigación en Sanidad Animal (CISA-INIA), Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos (Madrid), Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Juan Carlos Espinosa

    Centro de Investigación en Sanidad Animal (CISA-INIA), Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos (Madrid), Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6719-9902
  4. Chiara Maria Giulia De Luca

    Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
    Competing interests
    The authors declare that no competing interests exist.
  5. Federico Angelo Cazzaniga

    Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
    Competing interests
    The authors declare that no competing interests exist.
  6. Sara Maria Portaleone

    Department of Health Sciences, Otolaryngology Unit, ASST Santi Paolo e Carlo Università Degli Studi di Milano, Milan, Italy
    Competing interests
    The authors declare that no competing interests exist.
  7. Luigi Celauro

    Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore Di Studi Avanzati (SISSA), Trieste, Italy
    Competing interests
    The authors declare that no competing interests exist.
  8. Giuseppe Legname

    Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore Di Studi Avanzati (SISSA), Trieste, Italy
    Competing interests
    The authors declare that no competing interests exist.
  9. Giorgio Giaccone

    Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
    Competing interests
    The authors declare that no competing interests exist.
  10. Juan Maria Torres

    Centro de Investigación en Sanidad Animal (CISA-INIA), Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos (Madrid), Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0443-9232
  11. Fabio Moda

    Division of Neurology 5 and Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
    For correspondence
    Fabio.Moda@istituto-besta.it
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2820-9880

Funding

Ministero della Salute (GR-2013-02355724)

  • Fabio Moda

Ministero della Salute (Ricerca Corrente)

  • Fabio Moda

MJFF, ALZ, Alzheimer's Research UK and the Weston Brain Institute (BAND2015)

  • Fabio Moda

Euronanomed III (Speedy)

  • Fabio Moda

Spanish Ministerio de Economia y Competitividad (AGL2016-78054-R (AEI/FEDER,UE))

  • Juan Maria Torres

INIA (Fellowship FPI-SGIT-2015-02)

  • Alba Marín Moreno

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: We conducted animal experiments in accordance with the Code for Methods and Welfare Considerations in Behavioural Research with Animals (Directive 2010/63/EU) and made every effort to minimize suffering. Experiments developed in Centro de Investigación en Sanidad Animal-Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (Madrid, Spain) were evaluated by the Committee on the Ethics of Animal Experiments of the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria and approved by the General Directorate of the Madrid Community Government (permit no. PROEX 263-15)

Human subjects: Written informed consent for participation in research and all procedures for sample collection and experimental studies were in accordance with the 1964 Declaration of Helsinki and its later amendments and were approved by the Ethical Committee of "Fondazione IRCCS Istituto Neurologico Carlo Besta" (Milan, Italy).

Copyright

© 2021, Bistaffa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,693
    views
  • 142
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Edoardo Bistaffa
  2. Alba Marín Moreno
  3. Juan Carlos Espinosa
  4. Chiara Maria Giulia De Luca
  5. Federico Angelo Cazzaniga
  6. Sara Maria Portaleone
  7. Luigi Celauro
  8. Giuseppe Legname
  9. Giorgio Giaccone
  10. Juan Maria Torres
  11. Fabio Moda
(2021)
PMCA generated prions from the olfactory mucosa of patients with Fatal Familial Insomnia cause prion disease in mice
eLife 10:e65311.
https://doi.org/10.7554/eLife.65311

Share this article

https://doi.org/10.7554/eLife.65311

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Kavidha Reddy, Guinevere Q Lee ... Thumbi Ndung'u
    Research Article

    Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.